NKMAX Appoints New CFO for US Corporation... "Expecting Accelerated Business Development"

[Asia Economy Reporter Hyunseok Yoo] NKMAX announced on the 8th that its U.S. subsidiary NKGen Biotech (formerly NKMAX America) has newly appointed a Chief Financial Officer (CFO).

NKGen Biotech, a 100% U.S. subsidiary of NKMAX, will accelerate fundraising and subsequent procedures. The newly appointed CFO, Philip Moody, graduated from UC Berkeley's Haas School of Business and has extensive experience overseeing financial operations and driving IPOs at multiple global biotech companies including Paxvax, BTG plc, Peplin, and Chiron Corporation.

Philip Moody, CFO, stated, “NKGen Biotech possesses excellent cell therapy manufacturing facilities and is a leading company in the NK cell therapy platform and pipeline, with limitless growth potential. I am honored to join NKGen Biotech and will work to establish a solid financial foundation and strategy going forward.”

Park Sangwoo, CEO of NKMAX, expressed high expectations for future business progress, saying, “The newly joined CFO is a financial strategy expert who will focus all capabilities on financial operations and strategy development, which will be key to the growth of our U.S. subsidiary.”